Citations

Clear

3138 citation(s) found for "Smith, AM".

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.
Hurwitz, Herbert I. , Pitot, Henry C., Smith, David C. , Brill, Jeffrey Mark, Vuagniaux, Grégoire, Rouits, Elisabeth , Zanna, Claudio , Sorensen, John M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2532-2532

10.1200/jco.2014.32.15_suppl.2532 Get It

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-posi
Piccart, Martine , Holmes, Andrew , Baselga, José , Viale, Giuseppe , Zujewski, Jo Anne , Goldhirsch, Aron, Jackisch, Christian , Láng, István, Smith, Ian E., Boyle, Frances , Gelber, Richard D. , Perez, Edith A. , Azambuja, Evandro de , Dueck, Amylou C. , Zujewski, Jo Anne , Santillana, Sergio, Pritchard, Kathleen I. , Wolff, Antonio C. , Untch, Michael , Xu, Binghe , Gómez, Henry

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA4-LBA4

10.1200/jco.2014.32.15_suppl.lba4 Get It

NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.
Park, Haeseong , Qin, Rui , Atherton, Pamela J. , Barton, Debra L. , Sturtz, Keren , Dakhil, Shaker R. , Anderson, Daniel M. , Stella, Philip J., Puttabasavaiah, Suneetha, Le‐Lindqwister, Nguyet, Padula, Gilbert D. A. , Loprinzi, Charles L. , Smith, Thomas J.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 9508-9508

10.1200/jco.2014.32.15_suppl.9508 Get It

Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML).
Litzow, Mark R. , Morris, Lawrence E. , Levy, Moshe , Gojo, Ivana , Gocke, Christopher D. , Rosner, Gary L. , Greer, Jacqueline M., Cain, Joan McFadden, Little, Richard F. , Wright, John Joseph, Doyle, L. Austin, Karp, Judith E. , Zeidner, Joshua F. , Foster, Matthew C , Blackford, Amanda , Strickland, Stephen Anthony , Lancet, Jeffrey E. , Bose, Prithviraj , Tibes, Raoul , Smith, B. Douglas

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7002-7002

10.1200/jco.2014.32.15_suppl.7002 Get It

Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance).
Pachman, Deirdre R. , Qin, Rui , Seisler, Drew K., Beutler, Andreas S. , Ta, Lauren E., Lafky, Jacqueline M., Wagner‐Johnston, Nina D. , Ruddy, Kathryn J. , Dakhil, Shaker R. , Loprinzi, Charles L. , Lavoie Smith, Ellen M , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3595-3595

10.1200/jco.2014.32.15_suppl.3595 Get It

Determining the utility of standard hospital microbiology testing: Comparing standard microbiology cultures with DNA sequence analysis in patients with chronic sinusitis
Rapoport, Sarah K. , Smith, Alyssa J. , Bergman, Maxwell , Scriven, Kelly A., Mikula, Suzette, Brook, Itzhak

Mayo Clinic

World Journal of Otorhinolaryngology - Head and Neck Surgery | January 3, 2019 | Volume: 5 | Issue: 2 | Pages: 82-87

10.1016/j.wjorl.2018.11.001 | PMID 31334486 Get It

Objective To demonstrate DNA sequencing analysis (DNAsa) of sinus cultures in patients with CRS is a reliable method of detecting pathogens in polymicrobial CRS infections. Methods After obtaining Institutional Review Board approval for this prospective cohort study, we selected a random sample of 50 patients with CRS at Medstar Georgetown University Hospital between September 2016 and March 2017. We defined CRS as a history of rhinosinusitis refractory to maximal medical therapy and prior endoscopic sinus surgery. Patients demonstrating active purulence in a sinus cavity were prospectively selected to undergo standard hospital cultures (SHC) and DNAsa cultures. Organisms identified in both methods were compared for each patient. Results Specimens were obtained from 29 female and 16 male patients with a mean age of 50 years. A total of 45 cultures were included in our final analysis; five cultures were excluded after inappropriate laboratory processing. Results from these patients were compared and analyzed. Cohen's weighted kappa analysis showed agreement between the two testing methods in identifying predominant microorganisms. DNAsa detected 31.9% more microorganisms compared to SHC ( P < 0.05). When multiple microorganisms were detected, DNAsa yielded more positive results compared to SHC ( P < 0.05). Conclusions DNAsa detects all microorganisms identified by SHC as well as predominant microorganisms not detected by SHC. Thus molecular pathogen identification may be more reliable for identifying multiple microorganisms as compared to standard culture techniques that identify only one or two microorganisms. In recalcitrant cases of CRS, DNAsa may provide better guidance in selection of appropriate antimicrobial treatment.
Postoperative proton therapy for pancreatic cancer patients enrolled on the Proton Collaborative Group (PCG) registry.
Nichols, R.C., Morris, Christopher G. , Prabhu, Kiran, Hartsell, William F. , Cahlon, Oren, McGee, L.A. , Vargas, Carlos , Apisarnthanarax, Smith

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 513-513

10.1200/jco.2018.36.4_suppl.513 Get It

513 Background: The PCG registry is a multicenter registry for patients receiving proton therapy for various malignancies. The current abstract reviews the outcomes for patients receiving postoperative proton therapy for resected pancreatic cancer. Methods: From March, 2013 to August,2016 18 patients with resected pancreatic adenocarcinoma received postoperative proton therapy. The current study reviews the pretreatment characteristics and outcomes of these patients. Results: Median age -70 years (range 52 to 79); Males 12, Females 6; pT Stage -T2–4, T3–13, T4–1; N Stage -N1–12, N0–6; Margin Status -Close-8, Positive-4, Negative-6; Surgical approach -open-16, laparoscopic 2; Operations performed: standard pancreaticoduodenectomy-11, pylorus sparing pancreaticoduodenectomy-4, total pancreatectomy-1; Pancreaticoduodenectomy with portal vein reconstruction –1; Pancreaticoduodenectomy with irreversible electroporation. Median lymph nodes taken-16.50 (range 3 to 72); Median lymph nodes positive-1.5 (range 0 to 7); PNI positive-9, PNI negative-2, PNI unknown-4; LVI positive-7, LVI negative-6, LVI unknown-5; Median tumor size –3.1cm (range 2.2 to 6.2); Median dose delivered –50.51Gy(RBE) (range 27.88 to 54.00); Median treatment duration –38 calendar days (range 25 to 48); One patient died during treatment. One additional patient demonstrated grade 3 toxicity (anorexia, nausea, diarrhea). Only one patient’s treatment was protracted by more than 5 days. Median available follow up is 1.1 years (range 0.07 to 3.4 years); 2 year survival 37%. Conclusions: Postoperative proton therapy after pancreatectomy was well tolerated without treatment interruption or severe toxicity.
Factors at de novo donor‐specific antibody initial detection associated with allograft loss: a multicenter study
Schinstock, Carrie A. , Dadhania, Darshana M. , Everly, Matthew J. , Smith, Byron H. , Gandhi, Manish J. , Farkash, Evan A. , Samaniego, Milagros , Stegall, Mark D. , Smith, Byron , Gandhi, Manish, Stegall, Mark D , Schinstock, Carrie , Sharma, Vijay Kumar , Samaniego-Picota, Milagros

Mayo Clinic

Transplant International | December 31, 2018 | Volume: 32 | Issue: 5 | Pages: 502-515

10.1111/tri.13395 | PMID 30597643 Get It

Association of Kidney Function With 30-Day and 1-Year Poststroke Mortality and Hospital Readmission
Husseini, Nada El , Sheng, Shubin , Schulte, Phillip J. , Xian, Ying , Goldstein, Larry B. , Fonarow, Gregg C. , Smith, Eric Edward , Ju, Christine , Schwamm, Lee H. , Hernandez, Adrian F.

Mayo Clinic

Stroke | December 26, 2018 | Volume: 49 | Issue: 12 | Pages: 2896-2903

10.1161/strokeaha.118.022011 | PMID 30571413 Get It

Background and Purpose— Kidney dysfunction is common among patients hospitalized for ischemic stroke. Understanding the association of kidney disease with poststroke outcomes is important to properly adjust for case mix in outcome studies, payment models and risk-standardized hospital readmission rates. Methods— In this cohort study of fee-for-service Medicare patients admitted with ischemic stroke to 1579 Get With The Guidelines-Stroke participating hospitals between 2009 and 2014, adjusted multivariable Cox proportional hazards models were used to determine the independent associations of estimated glomerular filtration rate (eGFR) and dialysis status with 30-day and 1-year postdischarge mortality and rehospitalizations. Results— Of 204 652 patients discharged alive (median age [25th–75th percentile] 80 years [73.0–86.0], 57.6% women, 79.8% white), 48.8% had an eGFR ≥60, 26.5% an eGFR 45 to 59, 16.3% an eGFR 30 to 44, 5.1% an eGFR 15 to 29, 0.6% an eGFR <15 without dialysis, and 2.8% were receiving dialysis. Compared with eGFR ≥60, and after adjusting for relevant variables, eGFR <45 was associated with increased 30-day mortality with the risk highest among those with eGFR <15 without dialysis (hazard ratio [HR], 2.09; 95% CI, 1.66–2.63). An eGFR <60 was associated with increased 1-year poststroke mortality that was highest among patients on dialysis (HR, 2.65; 95% CI, 2.49–2.81). Dialysis was also associated with the highest 30-day and 1-year rehospitalization rates (HR, 2.10; 95% CI, 1.95–2.26 and HR, 2.55; 95% CI, 2.44–2.66, respectively) and 30-day and 1-year composite of mortality and rehospitalization (HR, 2.04; 95% CI, 1.90–2.18 and HR, 2.46; 95% CI, 2.36–2.56, respectively). Conclusions— Within the first year after index hospitalization for ischemic stroke, eGFR and dialysis status on admission are associated with poststroke mortality and hospital readmissions. Kidney function should be included in risk-stratification models for poststroke outcomes.
What Is the Optimal Placebo for Clinical Trials of Nerve Blocks in Headache?: An N‐of‐1 Study of Lactated Ringer’s
Potter, Jamie L., Robblee, Jennifer , Robblee, Jennifer V, Robblee, Jennifer V , Smith, Jonathan H.

Mayo Clinic

Headache: The Journal of Head and Face Pain | December 21, 2018 | Volume: 59 | Issue: 1 | Pages: 108-109

10.1111/head.13441 | PMID 30575969 Get It